Observational study links IKZF1plus genotype and ABL1 mutations to worse outcomes in adults with BCR::ABL1-positive ALL, suggesting improved risk stratification.
Key Points
To investigate the prognostic significance of IKZF1plus genotype and ABL1 mutations in adult BCR::ABL1-positive ALL.
Included newly diagnosed adult BCR::ABL1+ ALL patients from June 2014 to December 2024
Patients treated with TKI-based VIP regimen and recommended for allo-HSCT
Utilized MLPA for IKZF1plus genotyping and PCR for mutation analysis and MRD monitoring
246 patients categorized by IKZF1plus genotype and ABL1 mutation analysis
T315I mutation associated with poorer overall survival (34.4%) compared to non-T315I (61.7%) and no mutation (91.2%) groups
IKZF1plus/T315I subgroup showed lowest 3-year OS (21.2%), while allo-HSCT improved outcomes significantly